Table 2.
Study drug exposure
| DTP (N = 25) | |
|---|---|
| Number of cycles delivered | |
| Median (range) for trastuzumab | 14.5 cycles (3–36) |
| Median (range) for pertuzumab | 14.5 cycles (0–34) |
| Median (range) for eribulin | 10.0 cycles (3–34) |
| Relative dose intensity (%) | |
| Median (range) for trastuzumab | 97.1% (29.0–104.5) |
| Median (range) for pertuzumab | 95.1% (0–104.5) |
| Median (range) for eribulin | 96.4% (23.3–115.4) |
| Dose omissions*, n (%) | 18 (72.0%) |
| Dose reductions, n (%) | 6 (24.0%) |
| Dose delays, n (%) | 4 (16.0%) |
| Dose interruptions**, n (%) | 7 (28.0%) |
*The same patients had several reasons
**The same patients had several adverse events